Market Research Logo

Chronic Lymphocytic Leukemia: Epidemiology Forecast to 2027

Chronic Lymphocytic Leukemia: Epidemiology Forecast to 2027

Summary

Chronic lymphocytic leukemia (CLL) (International Statistical Classification of Diseases and Related Health Problems, 10th Revision [ICD-10] code = C91.1), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection.

GlobalData epidemiologists utilized national databases and robust peer-reviewed journal articles to build the CLL diagnosed incident and diagnosed prevalent cases forecast for the 7MM. The disease definition for CLL was consistent with the ICD-10 code C91.1. Whenever available, country-specific sources were utilized. In cases of data scarcity, appropriate proxies were used to fill the data gaps.

The diagnosed incident cases of CLL in the 7MM will increase from 41,974 cases in 2017 to 50,474 cases in 2027, at an Annual Growth Rate (AGR) of 2.03% over the forecast period. For the majority of the forecast period, the US will have the highest number of diagnosed incident cases of CLL. GlobalData epidemiologists attribute the growth in the diagnosed incident cases of CLL in the 7MM to the moderately rising trend in incidence in the 7MM, combined with the changing population demographics in the respective markets.

Scope

  • The Chronic Lymphocytic Leukemia (CLL) Epidemiology Report provides an overview of the risk factors and global trends of CLL in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Canada).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident cases of CLL segmented by age (for ages 18 years and older) and sex. The CLL diagnosed incident cases are segmented by Rai stage, modified Rai stage, and Binet stage at diagnosis, as well as high-risk cytogenetics for the 7MM. Additionally, GlobalData epidemiologists provide a forecast for the diagnosed prevalent cases of CLL in the 7MM. To forecast the diagnosed incident and diagnosed prevalent cases of CLL in the 7MM, GlobalData epidemiologists used data from nationally representative, population-based studies for the 7MM.
  • The CLL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The CLL Epidemiology report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global CLL market.
  • Quantify patient populations in the global CLL market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CLL therapeutics in each of the markets covered.
  • Understand magnitude of CLL patient population by stage.


1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Chronic Lymphocytic Leukemia: Executive Summary 4
2.1 Related Reports 6
2.2 Upcoming Reports 6
3 Epidemiology 7
3.1 Disease Background 7
3.2 Risk Factors and Comorbidities 7
3.3 Global and Historical Trends 8
3.4 Forecast Methodology 11
3.4.1 Sources Used 11
3.4.2 Forecast Assumptions and Methods - Population 20
3.4.3 Forecast Assumptions and Methods - Diagnosed Incident Cases of CLL 20
3.4.4 Diagnosed Incident Cases by Stage at Diagnosis (Rai Staging and Modified Rai Staging) 23
3.4.5 Diagnosed Incident Cases by Stage at Diagnosis (Binet Staging) 23
3.4.6 High-Risk Cytogenetics (11q Deletion, 13q Deletion, 17p Deletion, p53 mutation, CD38, ZAP70 and IGHV [Unmutated]) Among the Diagnosed Incident Cases of CLL 24
3.4.7 Forecast Assumptions and Methods - Diagnosed Prevalent Cases of CLL 26
3.5 Epidemiological Forecast for CLL (2017-2027) 27
3.5.1 Diagnosed Incident Cases of CLL 27
3.5.2 Age-Specific Diagnosed Incident Cases of CLL 29
3.5.3 Sex-Specific Diagnosed Incident Cases of CLL 30
3.5.4 Diagnosed Incident Cases of CLL by Rai Stage at Diagnosis 31
3.5.5 Diagnosed Incident Cases of CLL by Modified Rai Stage at Diagnosis 32
3.5.6 Diagnosed Incident Cases of CLL by Binet Stage at Diagnosis 33
3.5.7 Diagnosed Incident Cases of CLL by High-Risk Cytogenetics 34
3.5.8 Diagnosed Prevalent Cases of CLL 35
3.6 Discussion 36
3.6.1 Epidemiological Forecast Insight 36
3.6.2 Limitations of the Analysis 36
3.6.3 Strengths of the Analysis 37
4 Appendix 38
4.1 Bibliography 38
4.2 About the Authors 41
4.2.1 Epidemiologist 41
4.2.2 Reviewers 41
4.2.3 Global Director of Therapy Analysis and Epidemiology 42
4.2.4 Global Head and EVP of Healthcare Operations and Strategy 42
4.3 About GlobalData 43
4.4 Contact Us 43
4.5 Disclaimer 43
1.1 List of Tables
Table 1: Risk Factors and Comorbid Conditions Associated with CLL 8
Table 2: 7MM, Diagnosed Incident Cases of CLL by High-Risk Cytogenetics, Both Sexes, Ages ≥18 Years, N, 2017 34
1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥18 Years, N, 2017 and 2027 5
Figure 2: 7MM, Diagnosed Prevalent Cases of CLL, Both Sexes, Ages ≥18 Years, N, 2017 and 2027 6
Figure 3: 7MM, Age-Standardized Diagnosed Incidence of CLL (Cases per 100,000 Population), Men, Ages ≥18 Years, 2017-2027 9
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of CLL (Cases per 100,000 Population), Women, Ages ≥18 Years, 2017-2027 10
Figure 5: 7MM, Sources Used, Diagnosed Incident Cases of CLL 11
Figure 6: 7MM, Sources Used, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Rai Staging and Modified Rai Staging) 12
Figure 7: 7MM, Sources Used, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Binet Staging) 13
Figure 8: 7MM, Sources Used, 11q and 13q Deletion Among the Diagnosed Incident Cases of CLL 14
Figure 9: 7MM, Sources Used, 17p Deletion Among the Diagnosed Incident Cases of CLL 15
Figure 10: 7MM, Sources Used, TP53 Among the Diagnosed Incident Cases of CLL 16
Figure 11: 7MM, Sources Used, CD38 Among the Diagnosed Incident Cases of CLL 17
Figure 12: 7MM, Sources Used, ZAP70 Among the Diagnosed Incident Cases of CLL 18
Figure 13: 7MM, Sources Used, IGHV (Unmutated) Among the Diagnosed Incident Cases of CLL 19
Figure 14: 7MM, Sources Used, Diagnosed Prevalent Cases of CLL 20
Figure 15: 7MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥18 Years, N, 2017 28
Figure 16: 7MM, Age-Specific Diagnosed Incident Cases of CLL, Both Sexes, N, 2017 29
Figure 17: 7MM, Sex-Specific Diagnosed Incident Cases of CLL, Ages ≥18 Years, N, 2017 30
Figure 18: 7MM, Diagnosed Incident Cases of CLL by Rai Stage at Diagnosis, Both Sexes, Ages ≥18 Years, N, 2017 31
Figure 19: 7MM, Diagnosed Incident Cases of CLL by Modified Rai Stage at Diagnosis, Both Sexes, Ages ≥18 Years, N, 2017 32
Figure 20: 7MM, Diagnosed Incident Cases of CLL by Binet Stage at Diagnosis, Both Sexes, Ages ≥18 Years, N, 2017 33
Figure 21: 7MM, Diagnosed Prevalent Cases of CLL, Both Sexes, Ages ≥18 Years, N, 2017 35

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report